BioMarin Pharmaceutical Inc (BMRN)-医療機器分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013831)
◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013831
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals that treat serious diseases and medical conditions. The company offers products for the treatment of various diseases such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product portfolio consists of products and multiple clinical and preclinical product candidates. The company operates through its manufacturing facilities in Novato, California and has its presence in US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc (BMRN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioMarin Pharmaceutical Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
BioMarin Pharmaceutical Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
BioMarin Pharmaceutical Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
BioMarin Pharmaceutical Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
BioMarin Pharmaceutical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
BioMarin Pharmaceutical Inc, Medical Equipment, Deal Details 10
Partnerships 10
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 10
Zacharon Pharma Enters Into Licensing Agreement With Arup Labs For Sensi-Pro Assay 11
Equity Offering 12
BioMarin Pharma Prices Public Offering of Shares for USD720 Million 12
BioMarin Pharma Completes Public Offering Of Shares For US$119.3 Million 13
Debt Offering 14
BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 14
BioMarin Pharma Completes Public Offering Of Notes Due 2018 For US$375 Million 15
BioMarin Pharma Completes Public Offering Of Notes Due 2020 For US$375 Million 17
Acquisition 19
Roche Rumored To Acquire BioMarin Pharma For US$13.5 Billion 19
BioMarin Pharma Acquires Zacharon Pharma For US$10 Million 20
BioMarin Pharmaceutical Inc – Key Competitors 21
BioMarin Pharmaceutical Inc – Key Employees 22
BioMarin Pharmaceutical Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 24
Recent Developments 25
Financial Announcements 25
Oct 26, 2017: BioMarin Announces Third Quarter 2017 Financial Results 25
Aug 02, 2017: BioMarin Announces Second Quarter 2017 Financial Results 29
May 04, 2017: BioMarin Announces First Quarter 2017 Financial Results 31
Feb 23, 2017: BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results 33
Oct 27, 2016: BioMarin Announces Third Quarter 2016 Financial Results 35
Apr 28, 2016: BioMarin Announces First Quarter 2016 Financial Results 37
Feb 25, 2016: BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results 39
Corporate Communications 41
Oct 03, 2017: BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors 41
Jul 18, 2016: BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg 42
Jan 04, 2016: BioMarin Announces Addition of David Pyott, Former Allergan Chairman and CEO, to Company’s Board of Directors 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
BioMarin Pharmaceutical Inc, Medical Equipment, Key Facts, 2016 2
BioMarin Pharmaceutical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
BioMarin Pharmaceutical Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
BioMarin Pharmaceutical Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
BioMarin Pharmaceutical Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
BioMarin Pharmaceutical Inc, Deals By Market, 2011 to YTD 2017 8
BioMarin Pharmaceutical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 10
Zacharon Pharma Enters Into Licensing Agreement With Arup Labs For Sensi-Pro Assay 11
BioMarin Pharma Prices Public Offering of Shares for USD720 Million 12
BioMarin Pharma Completes Public Offering Of Shares For US$119.3 Million 13
BioMarin Pharma Completes Underwriters Exercise of Over-Allotment Option of 0.599% Notes Due 2024 for USD45 Million 14
BioMarin Pharma Completes Public Offering Of Notes Due 2018 For US$375 Million 15
BioMarin Pharma Completes Public Offering Of Notes Due 2020 For US$375 Million 17
Roche Rumored To Acquire BioMarin Pharma For US$13.5 Billion 19
BioMarin Pharma Acquires Zacharon Pharma For US$10 Million 20
BioMarin Pharmaceutical Inc, Key Competitors 21
BioMarin Pharmaceutical Inc, Key Employees 22
BioMarin Pharmaceutical Inc, Other Locations 23
BioMarin Pharmaceutical Inc, Subsidiaries 23
BioMarin Pharmaceutical Inc, Joint Venture 24

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ BioMarin Pharmaceutical Inc (BMRN)-医療機器分野:企業M&A・提携分析(BioMarin Pharmaceutical Inc (BMRN) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆